Efficacy and Safety of Atrasentan in Patients With Cardiovascular Risk and Early Atherosclerosis
| العنوان: | Efficacy and Safety of Atrasentan in Patients With Cardiovascular Risk and Early Atherosclerosis |
|---|---|
| المؤلفون: | Abhiram Prasad, Rebecca E. Nelson, Amir Lerman, Lilach O. Lerman, David R. Holmes, Bailey Kent, Eugenia Raichlin, Verghese Mathew, Geralyn M. Pumper |
| المصدر: | Hypertension. 52:522-528 |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health), 2008. |
| سنة النشر: | 2008 |
| مصطلحات موضوعية: | Adult, Blood Glucose, Male, medicine.medical_specialty, Pyrrolidines, Endothelin A Receptor Antagonists, Hemodynamics, Blood Pressure, Coronary Artery Disease, Kidney, Placebo, Gastroenterology, Article, Coronary artery disease, chemistry.chemical_compound, Risk Factors, Internal medicine, Internal Medicine, Edema, Humans, Medicine, Antihypertensive Agents, Metabolic Syndrome, Creatinine, Endothelin-1, business.industry, Atrasentan, Middle Aged, Lipid Metabolism, Receptor, Endothelin A, medicine.disease, Treatment Outcome, Blood pressure, chemistry, Hypertension, Cardiology, Female, Metabolic syndrome, business, Endothelin receptor, Follow-Up Studies, medicine.drug |
| الوصف: | Endothelin plays an important role in the pathogenesis of atherosclerosis. The aim of the study was to evaluate the safety and hemodynamic and metabolic responses to 6 months treatment with atrasentan, the selective endothelin-A receptor antagonist. Seventy-two patients with multiple cardiovascular risk factors and nonobstructive coronary artery disease on coronary angiogram were randomly assigned in a double-blind manner to atrasentan or placebo. Mean aortic blood pressure decreased from 92±10 to 80±10 mm Hg ( P P =0.84). The difference between the groups was significant ( P P =0.011). Fasting glucose ( P =0.026), glycosylated hemoglobin level ( P =0.041), triglyceride l ( P =0.013), lipoprotein-A ( P =0.046), and uric acid levels ( P =0.048) decreased significantly in the atrasentan group compared with the placebo group. No progression of angiographic coronary disease was observed. The most common adverse effects with atrasentan were nasal stuffiness, headache, and edema. In conclusion, 6 months of treatment with atrasentan results in a reduction of blood pressure and improvement in glucose and lipid metabolism. These findings suggest the beneficial role of atrasentan in the treatment of hypertension and metabolic syndrome. |
| تدمد: | 1524-4563 0194-911X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c3506c7f8f5d34def6899dd8ca51cbfTest https://doi.org/10.1161/hypertensionaha.108.113068Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....4c3506c7f8f5d34def6899dd8ca51cbf |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15244563 0194911X |
|---|